Dendreon Corp fka DNDNQ

[p3analyze]

I second Ocyan's point - so long as the sensitivity analyses confirmed the 0.06 p-value was not due to imbalance in known prognostic variables, I would have no problem letting the financial interest non-conflicted ODAC doctors decide whether there is a good benefit risk ratio and sufficient unmet medical need that warrants approval. Note that neither nexavar nor sutent showed a statistially significant survival in RCC.